跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
cell-based therapy
首页
药物
cell-based therapy
cell-based therapy
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
SYSTEMS AND METHODS FOR COORDINATING MANUFACTURING OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY
EP 4139440 B1
申请人: IOVANCE BIOTHERAPEUTICS INC
优先权: 2020
CN
EP
US
WO
14 件公开
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TET2 ENGINEERED T CELL THERAPY
EP 3953379 A4
申请人: PACT PHARMA INC
优先权: 2019
CN
EP
US
WO
11 件公开
SOMATOSTATIN RECEPTOR-BASED CANCER THERAPY
EP 2613791 A2
申请人: UNIV TEXAS
优先权: 2010
EP
US
WO
10 件公开
TARGETED LIGAND-PAYLOAD BASED DRUG DELIVERY FOR CELL THERAPY
EP 3583218 B1
申请人: PURDUE RESEARCH FOUNDATION
优先权: 2017
CN
EP
US
WO
8 件公开
CELL-BASED VEHICLES FOR POTENTIATION OF VIRAL THERAPY
EP 4371565 A1
申请人: CALIDI BIOTHERAPEUTICS INC
优先权: 2018
CN
EP
US
WO
8 件公开
INDUCTION MEDIUM AND METHODS FOR STEM CELL CULTURE AND THERAPY
EP 4234032 A3
申请人: SANBIO INC
优先权: 2014
CN
EP
US
6 件公开
Modulating human Cas9-specific host immune response
US 11208640 B2
申请人: UNIV ARIZONA STATE
优先权: 2017
US
WO
6 件公开
NON-VIRAL VECTORS COMPRISING POLYPROPYLENEIMINE
EP 4077689 A1
申请人: UNIV GENT
优先权: 2019
CN
EP
US
WO
5 件公开
A SCORING METHOD FOR AN ANTI-B7H4 ANTIBODY-DRUG CONJUGATE THERAPY
EP 4211663 A2
申请人: MEDIMMUNE LTD
优先权: 2020
CN
EP
US
WO
5 件公开
RECOMBINANT LENTIVIRAL VECTOR FOR STEM CELL-BASED GENE THERAPY OF SICKLE CELL DISORDER
EP 3635120 A1
申请人: INST NAT SANTE RECH MED
优先权: 2017
EP
US
WO
5 件公开
第 1 / 10 页
上一页
下一页
药物
反馈